FDA GMP Quality Metrics Will Be Industry’s ‘SAT Score’
This article was originally published in PharmAsia News
Executive Summary
Number 2 pencils will not be required, but the U.S. FDA hopes manufacturing reports will make purchasing decisions resemble the college admissions process to some extent.
You may also be interested in...
FDA’s Plaisier: GMP Oversight Must Shift To Outcomes Model
In an interview with “The Pink Sheet,” the Office of Regulatory Affairs chief says she wants to chart her office’s activities based on their effect on public health instead of simply counting outputs like the number of inspections or 483s.
Compounding: Hamburg Asks Purchasers, States To Push Outsourcer Registration
Letters seek help encouraging large-scale compounders to register with the agency as outsourcing facilities; FDA also seeks nominations for its compounding advisory committee.
Califf Laments Shift To Ex-US Clinical Trials – As Well As Pace Of Reforms At Home
US FDA commissioner tells J.P. Morgan conference that the agency, industry, and the entire healthcare system need to change ‘at the same time’ in order for clinical trials to improve.